AGA Medical Corporation

AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER® Duct Occluder II

MINNEAPOLIS, Feb. 11 -- AGA Medical Corporation ( AGA") announced today it received European CE Mark approval for the AMPLATZER-® Duct Occluder II ("ADO II"). AGA also announced the immediate availability and launch of the device in Europe. The ADO II expands the AGA family of occlusion devices designed to occlude or close a patent ductus arteriosus ("PDA"), a type of congenital heart defect...

Read More »

AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER-® Duct Occluder II

MINNEAPOLIS, Feb. 11 -- AGA Medical Corporation ( AGA") announced today it received European CE Mark approval for the AMPLATZERÂ-® Duct Occluder II ("ADO II"). AGA also announced the immediate availability and launch of the device in Europe. The ADO II expands the AGA family of occlusion devices designed to occlude or close a patent ductus arteriosus ("PDA"), a type of congenital heart defect...

Read More »

AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II

MINNEAPOLIS, Aug. 24 / / -- AGA Medical Corporation ( AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II"). The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood vessel malformations in the peripheral...

Read More »

AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II

MINNEAPOLIS, Aug. 24 / / -- AGA Medical Corporation ( AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II"). The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood vessel malformations in the peripheral...

Read More »

AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER® Duct Occluder II

MINNEAPOLIS, Feb. 11 -- AGA Medical Corporation ( AGA") announced today it received European CE Mark approval for the AMPLATZER-® Duct Occluder II ("ADO II"). AGA also announced the immediate availability and launch of the device in Europe. The ADO II expands the AGA family of occlusion devices designed to occlude or close a patent ductus arteriosus ("PDA"), a type of congenital heart defect...

Read More »

AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER-® Duct Occluder II

MINNEAPOLIS, Feb. 11 -- AGA Medical Corporation ( AGA") announced today it received European CE Mark approval for the AMPLATZERÂ-® Duct Occluder II ("ADO II"). AGA also announced the immediate availability and launch of the device in Europe. The ADO II expands the AGA family of occlusion devices designed to occlude or close a patent ductus arteriosus ("PDA"), a type of congenital heart defect...

Read More »

AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II

MINNEAPOLIS, Aug. 24 / / -- AGA Medical Corporation ( AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II"). The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood vessel malformations in the peripheral...

Read More »

AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II

MINNEAPOLIS, Aug. 24 / / -- AGA Medical Corporation ( AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II"). The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood vessel malformations in the peripheral...

Read More »

All Topics